Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) (TRACY-1).

NCT06590857 is registered in ClinicalTrials.gov with RayzeBio, Inc. as lead sponsor.

NCT NCT06590857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06590857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) (TRACY-1).
Lead sponsor
RayzeBio, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 19, 2024
Completion date
November 30, 2033
Enrollment
64 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, bone metastases in subjects with advanced breast cancer, er+ breast cancer, er-positive her2-negative breast cancer, estrogen receptor-positive breast cancer, her2-negative breast cancer, hormone-sensitive breast cancer, hormone-sensitive metastatic breast cancer, metastatic breast cancer, metastatic breast cancer with bone involvement